{
    "data": [
        {
            "id": "urn:summary_document_transcript:quartr.com:2940281:0",
            "title": "PUBM: Strong Q4 and 2025 results set up double-digit growth and margin expansion for 2026",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 and full-year 2025 results exceeded expectations, driven by strong growth in CTV, mobile, and emerging AI-powered revenues. Strategic investments in AI and automation are fueling operational efficiencies and new revenue streams, with double-digit revenue growth and margin expansion expected in the second half of 2026.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940281:0-pubm-strong-q4-and-2025-results-set-up-double-digit-growth-and-margin-expansion-for-2026/",
            "pub_date": "2026-02-27 07:29:05",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940282:0",
            "title": "LASR: Record A&D growth and margin expansion drive strong 2025 results and positive 2026 outlook",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Record 2025 revenue and margin expansion were driven by robust A&amp;D growth and key contract wins. Exiting cutting and welding, the company is reallocating resources to high-growth defense and advanced manufacturing, supported by a strong balance sheet and new capital.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940282:0-lasr-record-a-d-growth-and-margin-expansion-drive-strong-2025-results-and-positive-2026-outlook/",
            "pub_date": "2026-02-27 07:29:06",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940283:0",
            "title": "OPRT: Strong 2025 results and 2026 guidance highlight profitability, cost discipline, and prudent credit management",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Delivered strong Q4 and full-year 2025 results with improved profitability, disciplined expense management, and reduced cost of capital. 2026 guidance projects stable revenue, lower interest expense, and higher adjusted EPS, while maintaining a cautious credit posture amid macro uncertainty.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940283:0-oprt-strong-2025-results-and-2026-guidance-highlight-profitability-cost-discipline-and-prudent-credit-management/",
            "pub_date": "2026-02-27 07:29:07",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940284:0",
            "title": "TLN: 2025 results beat expectations; 2026 outlook strong with data center-driven growth and M&A upside",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 and full-year 2025 results exceeded guidance, driven by acquisitions and strong operations. 2026 guidance is reaffirmed, with further upside expected from the pending Cornerstone deal and robust data center demand. Free cash flow per share is set to more than double year-over-year.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940284:0-tln-2025-results-beat-expectations-2026-outlook-strong-with-data-center-driven-growth-and-m-a-upside/",
            "pub_date": "2026-02-27 07:29:09",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940285:0",
            "title": "DNA: Annual cash burn cut by 55% as focus shifts to autonomous labs and AI-driven automation",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Restructuring and cost controls led to a 55% reduction in annual cash burn, with a strategic pivot to autonomous labs and divestiture of the biosecurity business. Major contract wins and AI collaborations highlight leadership in lab automation.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940285:0-dna-annual-cash-burn-cut-by-55-as-focus-shifts-to-autonomous-labs-and-ai-driven-automation/",
            "pub_date": "2026-02-27 07:29:10",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940286:0",
            "title": "DV: 2025 saw 14% revenue growth and strong margins, with 2026 guided for 8–10% growth and higher profitability",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Delivered 14% revenue growth and 33% adjusted EBITDA margin in 2025, driven by strong product innovation in social, CTV, and AI. Guidance for 2026 anticipates 8–10% revenue growth, higher margins, and continued capital returns, with growth led by new product adoption and sector diversification.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940286:0-dv-2025-saw-14-revenue-growth-and-strong-margins-with-2026-guided-for-8-10-growth-and-higher-profitability/",
            "pub_date": "2026-02-27 07:29:11",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940287:0",
            "title": "BCO: $6.6B deal forms a $10B revenue fintech leader with $200M synergies and strong cash flow",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>A $6.6B acquisition will create a $10B revenue, $2B EBITDA company with strong recurring revenue, $200M in cost synergies, and over $1B in free cash flow expected. The deal is highly accretive, with robust growth in AMS/DRS and a focus on rapid deleveraging.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940287:0-bco-6-6b-deal-forms-a-10b-revenue-fintech-leader-with-200m-synergies-and-strong-cash-flow/",
            "pub_date": "2026-02-27 07:29:13",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940288:0",
            "title": "PCRX: Record 2025 revenue and margins set stage for continued growth and global expansion in 2026",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>2025 saw record revenue and gross margins, driven by EXPAREL growth, expanded coverage, and strategic partnerships. 2026 guidance projects continued top-line growth, margin improvement, and robust pipeline advancement, with disciplined capital allocation and global expansion plans.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940288:0-pcrx-record-2025-revenue-and-margins-set-stage-for-continued-growth-and-global-expansion-in-2026/",
            "pub_date": "2026-02-27 07:29:14",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-26:newsml_AZN4SIKKB:0",
            "title": "Tokyo Feb core CPI rises 1.8% yr/yr",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>TOKYO, Feb 27 (Reuters) - Core consumer prices in Tokyo rose 1.8% in February from a year earlier, government data showed on Friday.</span></p><p class=\"\"><span>The core consumer price index for Japan’s capital, which includes oil products but excludes fresh food prices, compared with economists' median estimate for a 1.7% annual rise.</span></p><p class=\"\"><span>(Reporting by Tokyo Newsroom)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-26:newsml_AZN4SIKKB:0-tokyo-feb-core-cpi-rises-1-8-yr-yr/",
            "pub_date": "2026-02-27 07:30:00",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018940_20260226018940:0",
            "title": "Dicker Data Target Price Raised 9.5% to A$10.35/Share by Macquarie>DDR.AU",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018940_20260226018940:0/",
            "pub_date": "2026-02-27 07:30:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018942_20260226018946:0",
            "title": "City Developments 2025 Rev S$3.59B Vs. S$3.27B >C09.SG",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018942_20260226018946:0/",
            "pub_date": "2026-02-27 07:30:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018942_20260226018942:0",
            "title": "City Developments 2025 Net S$629.7M Vs. Net S$201.3M >C09.SG",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018942_20260226018942:0/",
            "pub_date": "2026-02-27 07:30:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3LI:0",
            "title": "MasTec Inc reports results for the quarter ended December 31 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>MasTec Inc </span><span> reported quarterly adjusted earnings of $2.48​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $1.44.  The mean expectation of twenty analysts for the quarter was for earnings of $1.95 per share. Wall Street expected results to range from $2.25  to $2.40 per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue rose 15.8% to $3.94 billion from a year ago; analysts expected $3.90 billion. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>MasTec Inc's reported EPS for the quarter was $1.81​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $160.5 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>MasTec Inc shares had risen by 31.2% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the construction &amp; engineering peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for MasTec Inc is $262.00, about 10.7% below its last closing price of $289.96</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>2.30</span></p></td><td><p class=\"\"><span>2.07</span></p></td><td><p class=\"\"><span>Missed</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>1.40</span></p></td><td><p class=\"\"><span>1.49</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>1.40</span></p></td><td><p class=\"\"><span>0.51</span></p></td><td><p class=\"\"><span>Missed</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>1.23</span></p></td><td><p class=\"\"><span>1.44</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3LI:0-mastec-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/",
            "pub_date": "2026-02-27 07:30:09",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940228:0",
            "title": "Definium Therapeutics Inc: Three pivotal Phase 3 readouts for DT120 ODT expected in 2026, with strong financial position",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Advanced late-stage pipeline with three pivotal Phase 3 readouts for DT120 ODT in GAD and MDD expected in 2026, supported by a strong cash position and commercial readiness. R&amp;D and G&amp;A expenses rose significantly, with net loss impacted by warrant revaluation. Cash runway extends into 2028.</span></p><p class=\"\"><span>Based on Definium Therapeutics Inc Q4 2025 Audio Transcript — Feb. 26 2026</span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940228:0-definium-therapeutics-inc-three-pivotal-phase-3-readouts-for-dt120-odt-expected-in-2026-with-strong-financial-position/",
            "pub_date": "2026-02-27 07:23:10",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940230:0",
            "title": "SNDX: 2025 revenue hit $172.4M, with both Revuforj and Niktimvo outperforming launch expectations",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue reached $172.4M in 2025, driven by strong launches of Revuforj and Niktimvo, both exceeding benchmarks. Robust growth, expanding indications, and a solid balance sheet position the company for profitability and continued pipeline advancement.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940230:0-sndx-2025-revenue-hit-172-4m-with-both-revuforj-and-niktimvo-outperforming-launch-expectations/",
            "pub_date": "2026-02-27 07:23:12",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940231:0",
            "title": "CRNX: Breakout 2025 with PALSONIFY launch, pipeline advances, and strong cash position for future growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>2025 marked a pivotal year with the successful U.S. launch of PALSONIFY, strong financial discipline, and robust pipeline progress, including positive EU regulatory momentum and new clinical trial initiations. Cash reserves and guidance support operations into 2030.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940231:0-crnx-breakout-2025-with-palsonify-launch-pipeline-advances-and-strong-cash-position-for-future-growth/",
            "pub_date": "2026-02-27 07:23:14",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940232:0",
            "title": "KIDS: Q4 2025 delivered record revenue growth, margin expansion, and first-ever positive free cash flow",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw 17% revenue growth, improved margins, and the first positive free cash flow, driven by strong performance across all segments and major product launches. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and free cash flow breakeven.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940232:0-kids-q4-2025-delivered-record-revenue-growth-margin-expansion-and-first-ever-positive-free-cash-flow/",
            "pub_date": "2026-02-27 07:23:15",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940233:0",
            "title": "PAR: Q4 saw double-digit revenue growth, record ARR, and accelerating AI-driven platform adoption",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 revenue rose 14% year-over-year to $120.1M, with record ARR growth and strong subscription momentum. AI-driven products and multiproduct deals fueled performance, while supply chain pressures impacted hardware margins. 2026 guidance calls for mid-teens ARR growth and improved margins.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940233:0-par-q4-saw-double-digit-revenue-growth-record-arr-and-accelerating-ai-driven-platform-adoption/",
            "pub_date": "2026-02-27 07:23:17",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940234:0",
            "title": "BDSX: Q4 delivered 41% revenue growth and first positive adjusted EBITDA, with 2026 guidance up 23%",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw 41% revenue growth and first-ever positive adjusted EBITDA, driven by lung diagnostics and expanded sales reach. 2026 guidance projects 23% revenue growth, with continued margin strength and operational leverage. Cash position strengthened by new financing and loan extension.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940234:0-bdsx-q4-delivered-41-revenue-growth-and-first-positive-adjusted-ebitda-with-2026-guidance-up-23/",
            "pub_date": "2026-02-27 07:23:17",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KS:0",
            "title": "Autodesk Inc reports results for the quarter ended January 31 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc </span><span> reported quarterly adjusted earnings of $2.67​​ per share for the quarter ended January 31, higher than the same quarter last year, when the company reported EPS of $2.29.  The mean expectation of twenty four analysts for the quarter was for earnings of $2.64 per share. Wall Street expected results to range from $2.48  to $2.77 per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue rose 18% to $1.85 billion from a year ago; analysts expected $1.91 billion. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc's reported EPS for the quarter was $1.60​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $316 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc shares had fallen by 24.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts was unchanged in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 29 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the software peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Autodesk Inc is $365.00, about 36% above its last closing price of $233.45</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Oct. 31 2025 </span></p></td><td><p class=\"\"><span>2.50</span></p></td><td><p class=\"\"><span>2.85</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jul. 31 2025 </span></p></td><td><p class=\"\"><span>2.45</span></p></td><td><p class=\"\"><span>2.67</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Apr. 30 2025 </span></p></td><td><p class=\"\"><span>2.45</span></p></td><td><p class=\"\"><span>2.62</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jan. 31 2025 </span></p></td><td><p class=\"\"><span>2.14</span></p></td><td><p class=\"\"><span>2.29</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KS:0-autodesk-inc-reports-results-for-the-quarter-ended-january-31-earnings-summary/",
            "pub_date": "2026-02-27 07:23:24",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZM2P5:0",
            "title": "Singapore's Olam Group annual profit jumps more than five-fold",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Singapore's Olam Group </span><span> reported a more than five-fold jump in annual profit on Friday, helped by strong performance across its businesses.</span></p><p class=\"\"><span>Olam, one of the world's biggest agricultural commodities traders, posted profit attributable of S$444.1 million ($351.34 million) for the year ended December 31, compared with S$86.4 million last year.</span></p><p class=\"\"><span>($1 = 1.2640 Singapore dollars)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZM2P5:0-singapore-s-olam-group-annual-profit-jumps-more-than-five-fold/",
            "pub_date": "2026-02-27 07:24:06",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KZ:0",
            "title": "Emergent BioSolutions Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc </span><span> reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $1.37.  The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. to range from -35 cents to 11 cents per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 23.6% to $231.10 million from a year ago; analysts expected $194.00 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc's reported EPS for the quarter was a loss of $1.04​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported a quarterly loss of $54.6 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc shares had fallen by 10.9% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 191.7% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 17.8% above its last closing price of $11.10</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>0.11</span></p></td><td><p class=\"\"><span>1.06</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.12</span></p></td><td><p class=\"\"><span>1.06</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.49</span></p></td><td><p class=\"\"><span>0.71</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2024 </span></p></td><td><p class=\"\"><span>0.44</span></p></td><td><p class=\"\"><span>0.05</span></p></td><td><p class=\"\"><span>Missed</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KZ:0-emergent-biosolutions-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:24:28",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM1Q6:0",
            "title": "Bain Capital Specialty Finance Q4 net income per share rises q-o-q",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Specialty finance firm's Q4 net investment income per share was $0.46</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Net income per share for Q4  was $0.43</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company declares first-quarter 2026 dividend of $0.42 per share</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>STRONG NET INVESTMENT INCOME - BCSF's net investment income per share was $0.46, covering dividends, driven by stable credit metrics and low non-accruals</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Q4 EPS</span></p></td></tr><tr><td><p class=\"\"><span>Beat/Miss</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>$0.43</span></p></td></tr><tr><td><p class=\"\"><span>Consensus Estimate</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The average consensus recommendation for the investment management &amp; fund operators peer group is \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Bain Capital Specialty Finance Inc is $14.50, about 13.7% above its February 26 closing price of $12.75</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM1Q6:0-bain-capital-specialty-finance-q4-net-income-per-share-rises-q-o-q/",
            "pub_date": "2026-02-27 07:24:40",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_slides:quartr.com:2940240:0",
            "title": "BCO: Merger forms a $10B revenue fintech leader, targeting $200M synergies and strong EPS growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>A merger will create a financial technology infrastructure leader with ~$10B revenue and ~$2B adjusted EBITDA, targeting $200M in annual cost synergies and strong free cash flow. The deal is expected to be 35% EPS accretive and close in Q1 2027, with a focus on growth, margin expansion, and shareholder value.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A2940240-00b6bc94d8f92ee72579c81b9cd63037\" target=\"_blank\">Brinks Company (The) [BCO] Slides Release — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2940240:0-bco-merger-forms-a-10b-revenue-fintech-leader-targeting-200m-synergies-and-strong-eps-growth/",
            "pub_date": "2026-02-27 07:24:40",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM1QN:0",
            "title": "Aura Minerals Q4 net revenue surges on higher gold, copper prices",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Canada-based gold miner's Q4 net revenue rose 88% YoY</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Adjusted EBITDA for Q4 hit record high, driven by higher production and metal prices</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company completed acquisition of MSG Gold Mine in December 2025</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Aura projects 2026 production to grow to 360,000–390,000 GEO</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company aims to exceed 600,000 GEO annually in coming years</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Aura plans capacity expansions at Borborema and Almas</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>HIGHER PRODUCTION - Aura's Q4 2025 production increased 23% YoY, driven by Borborema ramp-up and MSG acquisition</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>HIGHER METAL PRICES - Q4 2025 net revenue rose 88% YoY, aided by higher gold and copper prices</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>STABLE COSTS - Aura maintained stable costs, contributing to record Adjusted EBITDA in Q4 2025</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Q4 Revenue</span></p></td></tr><tr><td><p class=\"\"><span>Beat/Miss</span></p></td><td><p class=\"\"><span>Slight Miss*</span></p></td></tr><tr><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>$321.60 mln</span></p></td></tr><tr><td><p class=\"\"><span>Consensus Estimate</span></p></td><td><p class=\"\"><span>$324.45 mln (2 Analysts)</span></p></td></tr></tbody></table></div><p class=\"\"><span>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</span></p><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Aura Minerals Inc is $75.00, about 16.4% below its February 26 closing price of $89.74</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 8 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM1QN:0-aura-minerals-q4-net-revenue-surges-on-higher-gold-copper-prices/",
            "pub_date": "2026-02-27 07:24:55",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018918:0",
            "title": "Netflix to Invest $20B Content After Ceding Warner to Paramount — Market Talk",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Netflix is doubling down on its own content after declining to up the ante in a bidding war with Paramount for Warner Bros. Discovery. Netflix invest about $20 billion in quality films and series this year and expand its entertaining offering, and also plans to resume its share buyback program. The company had signed a deal for Warner's studios and HBO Max for $72 billion. The deal was \"a 'nice to have' at the right price, not a 'must have' at any price,\" Netflix's co-CEOs say in a statement. \"Netflix's business is healthy, strong and growing organically, powered by our slate and best-in-class streaming service.\" (kelly.cloonan@wsj.com)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018918:0/",
            "pub_date": "2026-02-27 07:25:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940201:0",
            "title": "QSR: Clear roadmap to 5%+ net restaurant growth and double-digit shareholder returns by 2028",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Management outlined a clear path to 5%+ net restaurant growth and 8% AOI growth by 2028, driven by international expansion, operational improvements, and disciplined capital allocation. Franchisee alignment, technology innovation, and refranchising are central to the strategy, with investment-grade leverage and increased shareholder returns targeted.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940201:0-qsr-clear-roadmap-to-5-net-restaurant-growth-and-double-digit-shareholder-returns-by-2028/",
            "pub_date": "2026-02-27 07:17:36",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KF:0",
            "title": "BioLife Solutions Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc </span><span> reported quarterly adjusted earnings of 22 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -4 cents.  The mean expectation of ten analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to 1 cents per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 19% to $24.76 million from a year ago; analysts expected $24.08 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc's reported EPS for the quarter was 1 cent​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $11.07 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc shares had fallen by 7.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 30% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, three analysts negatively revised earnings estimates</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for BioLife Solutions Inc is $32.00, about 29.8% above its last closing price of $22.48</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>0.22</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.04</span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.05</span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.05</span></p></td><td><p class=\"\"><span>0.26</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KF:0-biolife-solutions-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:17:41",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_TUA5BRHS0:0",
            "title": "Ginkgo Bioworks Reports Fourth Quarter And Full Year 2025 Financial Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Ginkgo Bioworks Holdings Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>GINKGO BIOWORKS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS, ANNOUNCES FOCUS ON AUTONOMOUS LABS OFFERINGS AND DIVESTITURE OF ITS NON-CORE BIOSECURITY BUSINESS</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA5BRHS0:0-ginkgo-bioworks-reports-fourth-quarter-and-full-year-2025-financial-results/",
            "pub_date": "2026-02-27 07:17:42",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KG:0",
            "title": "Puma Biotechnology Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc </span><span> reported quarterly adjusted earnings of 26 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 41 cents.  The lone analyst forecast for the quarter was for earnings of 23 cents per share. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 6.2% to $75.50 million from a year ago; analysts expected $51.00 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc's reported EPS for the quarter was 26 cents​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $8.8 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc shares had risen by 29.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 404.4% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, two analysts negatively revised earnings estimates</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is  \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 52% below its last closing price of $7.60</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2025 </span></p></td><td><p class=\"\"><span>0.23</span></p></td><td><p class=\"\"><span>0.26</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>0.10</span></p></td><td><p class=\"\"><span>0.17</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.02</span></p></td><td><p class=\"\"><span>0.12</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>0.10</span></p></td><td><p class=\"\"><span>0.39</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KG:0-puma-biotechnology-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:17:43",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        }
    ]
}